TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Argent Biopharma ( (AU:RGT) ) has issued an update.
Argent BioPharma announced the successful outcomes of its Annual General Meeting held on 28 November 2025, where all proposed resolutions were passed by poll. This includes key decisions such as the adoption of the remuneration report, election and re-election of directors, and ratifications of prior share issues. The approval of these resolutions supports the company’s strategic initiatives and strengthens its governance framework, potentially enhancing its market positioning and stakeholder confidence.
More about Argent Biopharma
Argent BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that address the balance between the nervous and immune systems. The company’s lead candidates, CannEpil® and CimetrA®, are aimed at treating drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. Argent BioPharma utilizes proprietary delivery platforms to enhance drug efficacy and is committed to addressing urgent unmet needs in central nervous system and systemic inflammation.
Average Trading Volume: 87,121
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.83M
See more data about RGT stock on TipRanks’ Stock Analysis page.